{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-26-000045","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2026-07-30T20:03:10+00:00","discovered_at":"2026-07-30T20:04:00.830113+00:00","generated_at":"2026-07-30T20:04:06.151656+00:00","sec_items":["2.02","9.01","7.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CareDx Q2 revenue $132M (+52% YoY); raises FY2026 revenue guidance to $490M-$500M","bullets":["Q2 revenue $132M (+52% YoY); Testing Services revenue $100M (+61% YoY) on ~58,000 tests.","GAAP net income $111M (incl. $113M gain on Lab Products sale) vs loss $9M YoY; non-GAAP EPS $0.37.","Adjusted EBITDA $25M vs $5M YoY; raised FY2026 revenue guidance to $490M-$500M (from $447M-$465M).","Raised FY2026 adjusted EBITDA guidance to $66M-$78M (from $43M-$57M).","Closed Lab Products divestiture to Eurobio Scientific and acquired Naveris; CMS finalized coverage for AlloSure/AlloMap."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-26-000045","json":"https://secwatch.observer/filing/0001217234-26-000045.json","markdown":"https://secwatch.observer/filing/0001217234-26-000045.md","text":"https://secwatch.observer/filing/0001217234-26-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000045/0001217234-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000045/cdna-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:04:06.151656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}